CytomX Therapeutics: Promising Varseta-M With Comfortable Runway
CTMX has the PROBODY platform, which I think potentially unlocks difficult oncology targets by limiting drug activity in healthy tissue. Their lead asset is Varseta-M, which has interesting early colorectal cancer activity. Yet, it still requires larger and more mature datasets. CTMX's pipeline has lined up a Varseta-M monotherapy update, combination-study data, and new gastrointestinal cohorts. These are several catalysts through 1H2027.
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics NASDAQ: CTMX said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers.
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to break-even earnings per share a year ago.
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CytomX Therapeutics: Cashed Up With Catalysts Ahead
In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although toxicity concerns can't be dismissed. Following the Q1'26 CRC data update, CTMX raised $234.2M, extending its cash runway and enabling broader Varseta-M development. CTMX's cash position of $346.7M supports operations into at least H2'28, with anticipated increased R&D spending as programs expand.
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.27 per share a year ago.
Small Cap or Megacap: Which Healthcare Stock Is Right for You?
Healthcare companies with different market caps offer different rewards and challenges.
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level
CytomX Therapeutics (CTMX) has generated significant excitement with strong early data for varsetatug masetecan in refractory colorectal cancer. Phase 1 results show 20–32% response rates and median PFS of 6.8–7.1 months, outperforming current treatments in this setting. CTMX is executing a $250 million equity raise, extending its cash runway and positioning for registrational studies, but remains pre-commercial.
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.22 per share a year ago.
